Serena Maria Boccia

Serena Maria Boccia

Auto-generated profile, based on publicly available information

Serena Maria Boccia

Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2025 in ESMO Open
Verified
Journal Article
Open access
Claudia MarchettiClaudia Marchetti
Claudia Marchetti
AFA. Fagotti
A. Fagotti
RFR. Fruscio
R. Fruscio
CCC. Cassani
C. Cassani
LIL. Incorvaia
L. Incorvaia
Domenica LorussoDomenica Lorusso
Domenica Lorusso

15 November 2025 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
SBSerena Maria Boccia
Serena Maria Boccia
MBMatteo Bruno
Matteo Bruno
CCCamilla Culcasi
Camilla Culcasi
FGFiorenza Guida
Fiorenza Guida
CSCarolina Maria Sassu
Carolina Maria Sassu
CMClaudia Marchetti
Claudia Marchetti

4 November 2025 in International Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
IAIonelia Apostol Adriana
Ionelia Apostol Adriana
MBMatteo Bruno
Matteo Bruno
CSCarolina Maria Sassu
Carolina Maria Sassu
SBSerena Maria Boccia
Serena Maria Boccia
LVLaura Vertechy
Laura Vertechy
Claudia MarchettiClaudia Marchetti
Claudia Marchetti
Background: Niraparib is approved for maintenance treatment of tubo-ovarian cancer patients, but data on older patients are limited. This retrospective study evaluated its safety and efficacy in primary advanced tubo-ovarian cancer, focusing on patients ≥ 75 years. Methods: Women aged ≥ 50 years diagnosed with primary high-grade serous tubo-ovarian cancer, treated with niraparib between 2019–2023, were enrolled. Patients were stratified into three groups: A (50–64 years), B (65–74 years), and C (≥ 75 years). The primary outcome was progression-free survival. The secondary outcomes were toxicity and dose reduction. Results: 127 patients were identified: 62 (48.8%) group A, 26 (20.5%) group B, and 39 (30.7%) group C. Baseline characteristics were comparable across groups, excluding a higher proportion of interval cytoreductive surgeries ( p = 0.001), residual tumor ( p = 0.01) and Eastern Cooperative Oncology Group (ECOG) > 1 ( p = 0.01) in group C. Most patients started niraparib at 200 mg/day with dose reductions primarily occurred within fourth cycle. Dose reductions were observed in 77.4%, 69.2% and 56.4% of patients in groups A, B, and C, respectively ( p = 0.08). In patients ≥ 75 years, 26 (66.7%) discontinued treatment due to disease progression (48.7%) or toxicity (17.9%). There were no significant differences in common or grade ≥ 3 adverse events between groups. Progression-free survival was 12 months (95%CI: 2.0–25.0) for group A, 29 months (95%CI: 11.0–52.0) for group B, and 16 months (95%CI: 1.0–31.0) for group C ( p = 0.78). Conclusions: Our findings suggest that niraparib is safe and well-tolerated in aged ≥ 75 years. Concerns about toxicity should not preclude the enrollment of elderly patients in treatment regiments.